Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan, is a mucolytic agent presented as a pharmaceutical preparation for oral and inhalation use. It helps reduce mucus viscosity and facilitates clearance in patients with respiratory conditions such as acute or chronic bronchitis.

GNH USA supplies Mucosolvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution. Our global network ensures reliable delivery to diverse healthcare settings.

Mucosolvan, a mucolytic agent, is used to manage conditions characterized by excessive or thickened respiratory secretions.

Acute bronchitis: improves mucus clearance, helping relieve productive cough in short‑term inflammation. Chronic bronchitis: reduces mucus viscosity, supporting long‑term airway hygiene in chronic disease. Respiratory tract infections with productive cough: facilitates expectoration, aiding recovery.

Like all medicines, Ambroxol may cause unwanted reactions, which are classified by frequency and severity.

Common Side Effects: - Cough irritation - Nausea - Diarrhea - Skin rash

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Severe skin reactions like Stevens‑Johnson syndrome

When prescribing or dispensing Mucosolvan, consider the following safety measures.

Assess patient history: verify no known hypersensitivity to ambroxol or related compounds. Use with caution in hepatic impairment: monitor liver function if long‑term therapy is planned. Avoid in severe renal dysfunction without medical supervision. Do not combine with other mucolytics unless directed by a healthcare professional. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ambroxol may interact with certain medicines, affecting their efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: may reduce mucociliary clearance, diminishing ambroxol’s benefit. - Certain antibiotics (e.g., macrolides): can increase risk of bronchospasm when combined with inhaled forms.

Moderate Interactions (Monitor Closely): - Bronchodilators: concurrent use may enhance cough reflex, requiring monitoring. - Warfarin: ambroxol may potentiate anticoagulant effect; check INR regularly.